GlassScriptPhysician profile
Viet T Dao
NPI 1861406225
$25,100.06
in general payments reported to CMS, 2019-2025
30 companies · $2,847 in 2025
The $2,847 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,935 · 2020: $2,532 · 2021: $3,611 · 2022: $3,783 · 2023: $2,316 · 2024: $3,076 · 2025: $2,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,239.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,518.59 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boston Scientific Corporation | $3,658.05 | 2019-2025 | Versacross Access Solution, Watchman Flx, Watchman |
| Abbvie INC. | $3,300.27 | 2019-2025 | Linzess, Creon, Viberzi |
| Gilead Sciences, INC. | $2,010.36 | 2019-2025 | Vemlidy, Epclusa |
| Amarin Pharma, INC. | $1,664.23 | 2019-2023 | |
| Lilly USA, LLC | $1,472.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,085.86 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $918.40 | 2019-2025 | Repatha |
| Glaxosmithkline, LLC. | $897.53 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Nestle Healthcare Nutrition INC. | $645.76 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $639.52 | 2022-2025 | |
| Allergan, INC. | $492.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $478.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $403.41 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.41 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $250.59 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $239.10 | 2020-2022 | |
| Medtronic Vascular, INC. | $205.51 | 2019-2020 | |
| Abbott Laboratories | $162.84 | 2022 | |
| Dexcom, INC. | $126.20 | 2019-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.30 | 2019 | |
| Radius Health, INC. | $118.41 | 2023-2024 | |
| Pfizer INC. | $51.86 | 2021-2025 | |
| Vivus LLC | $48.27 | 2021-2022 | |
| Eisai INC. | $24.26 | 2021 | |
| Astellas Pharma US INC | $22.07 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $21.75 | 2024 | Zoryve |
| Insulet Corporation | $21.24 | 2023 | Omnipod |
| Esperion Therapeutics, INC. | $20.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viet Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.